This article is more than 5 years old. Information may no longer be current.

EyeGate reports $13.3 million net loss in 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a $13.3 million net loss in 2016 compared with an $8.4 million net loss in 2015, according to a company press release.

Research and development costs were $8.4 million compared with $2.7 million in 2015, an increase attributed mostly to clinical activity, including the EGP-437 and CMHA-S product pipelines.

Cash and cash equivalents totaled $3.6 million as of Dec. 31, 2016, compared with $8.4 million the previous year.